Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24-10-2019
AVNphotolab / iStockphoto.com
A Brazilian federal judge has granted a preliminary injunction against a patent for US-based Gilead’s Sovaldi (sofosbuvir) drug, used to treat hepatitis C, following a complaint by a presidential candidate.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
INPI, patent, preliminary injunction, Gilead, hepatitis C, Gabriel Di Blasi, Di Blasi Parente & Associados, Marina Silva, Eduardo Jorge, Sovaldi
